Legal & General Group PLC Verrica Pharmaceuticals Inc. Transaction History

Legal & General Group PLC

  • $470 Billion
  • Q3 2024

A detailed history of Legal & General Group PLC transactions in Verrica Pharmaceuticals Inc. stock. As of the latest transaction made, Legal & General Group PLC holds 2,519 shares of VRCA stock, worth $20,026. This represents 0.0% of its overall portfolio holdings.

Number of Shares
2,519
Previous 2,519 -0.0%
Holding current value
$20,026
Previous $20,000 -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024
SELL
$5.89 - $9.56 $41 - $66
-7 Reduced 0.28%
2,519 $18,000
Q2 2023

Aug 14, 2023
BUY
$5.32 - $6.79 $13,438 - $17,151
2,526 New
2,526 $14,000
Q3 2022

Nov 14, 2022
SELL
$2.17 - $4.3 $2,391 - $4,738
-1,102 Closed
0 $0
Q2 2022

Aug 22, 2022
SELL
$1.81 - $8.93 $606 - $2,991
-335 Reduced 23.31%
1,102 $2,000
Q1 2021

May 17, 2021
SELL
$10.51 - $17.46 $1,313 - $2,182
-125 Reduced 8.0%
1,437 $22,000
Q3 2020

Nov 13, 2020
SELL
$6.16 - $10.3 $3,683 - $6,159
-598 Reduced 27.69%
1,562 $12,000
Q2 2020

Aug 14, 2020
BUY
$9.02 - $15.12 $2,327 - $3,900
258 Added 13.56%
2,160 $24,000
Q1 2020

May 14, 2020
SELL
$7.14 - $16.86 $4,098 - $9,677
-574 Reduced 23.18%
1,902 $21,000
Q4 2019

Feb 13, 2020
BUY
$13.08 - $17.43 $7,717 - $10,283
590 Added 31.28%
2,476 $39,000
Q1 2019

May 15, 2019
BUY
$7.95 - $14.07 $7,926 - $14,027
997 Added 112.15%
1,886 $20,000
Q3 2018

Nov 20, 2018
BUY
$13.94 - $19.88 $12,392 - $17,673
889 New
889 $14,000

Others Institutions Holding VRCA

# of Institutions
78
Shares Held
14.2M
Call Options Held
9.9K
Put Options Held
6.5K
View Full List

About Verrica Pharmaceuticals Inc.

VRCA Quotes by TradingView
  • Ticker VRCA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 41,094,100
  • Market Cap $327M
  • Description
  • Verrica Pharmaceuticals Inc., a dermatology therapeutics company, develops and commercializes treatments for people with skin diseases in the United States. The company's lead product candidate includes VP-102 for the treatment of molluscum contagiosum; that has completed Phase II clinical trial for the treatment of external genital warts; and w...
More about VRCA
Track This Portfolio

Track Legal & General Group PLC Portfolio

Follow Legal & General Group PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Legal & General Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Legal & General Group PLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email